: Patients were classified into precursor-B leukemia (pre-B Cell) and precursor T-cell leukemia (pre-T-Cell), based on flow cytometry and immunohistochemistry.
Diagnosis of childhood ALL is based on morphology, immunophenotyping
, karyotyping and gene expression1.
reagents 900 units, indicated by the participants3.
[1,2,3] Two widely used classifications are used, one by the French, American, and British group called the FAB Classification, and other by the World Health Organisation (WHO Classification), based on the morphologic findings, genetic abnormalities, clinical and Immunophenotyping
Multi-color flow cytometry was used for immunophenotyping
analysis and detection of NRP-2 levels on surfaces of various immune cell populations.
by flow cytometry showed the blast cells to express LCA, CD2, CD4, human leukocyte antigen (HLA)-DR, and CD56.
Using the latest in single-cell analysis technologies, Primity specialises in highly complex immunophenotyping
, intracellular signaling, cell sorting, and high-parameter CyTOF (mass cytometry) analysis.
Flow cytometric immunophenotyping
is of great value to diagnosis of natural killer cell neoplasms involving bone marrow and peripheral blood.
Standard lab tests to diagnose and classify leukemia includes--but are not limited to--microscopic examinations, immunophenotyping
, and a variety of chromosome tests (karyotyping).
Permanent pathology and flow cytometry immunophenotyping
analysis identified the tumor as a high-grade B-cell lymphoma with Burkitt morphology composed of intermediate-size malignant cells in a diffuse pattern with numerous tingible bodies creating a "starry sky" appearance (figure 2).
Second, in immunophenotyping
of B cell, the CD19-negative B linage is common and this can lead to errors in flow cytometry analysis (3,4).
Peripheral blood flow cytometric immunophenotyping
revealed a 40% population of aberrant B-lymphoblasts, that were CD45 (-), CD10 (+), CD22 (+), CD20 variably (+), CD19 (+), HLA-DR variably (+), CD34 partial (+), CD56 partial (+), Tdt (+), and negative for the remaining lymphoid and myeloid markers tested, including CD14, CD5, CD7, CD33, CD13, CD3, CD4, CD8, CD117, CD16, and MPO (Figure 2).